Gene targeting - Homing in on α2-adrenoceptor-subtype function

Trends in Pharmacological Sciences

Volumn 18, Issue 6, 1997, Pages 211-219

  MacDonald, E ^a   Kobilka, B K ^b   Scheinin, M ^c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ATIPAMEZOLE; CHLORPROMAZINE; CLONIDINE; DEXMEDETOMIDINE; IDAZOXAN; OXYMETAZOLINE; PRAZOSIN; RECEPTOR SUBTYPE; YOHIMBINE;

AMINO ACID SEQUENCE; DRUG RECEPTOR BINDING; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ENGINEERING; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; RECEPTOR AFFINITY; REVIEW;

EID: 0030844448     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(97)01063-8     Document Type: Review

References (64)

1. Harrison J. K., Pearson W. R., Lynch K. R. Trends Pharmacol. Sci. 12:1991;62-67.
2. Kobilka B. K.et al. Science. 238:1987;650-656.
3. Regan J. W.et al. Proc. Natl. Acad. Sci. U. S. A. 85:1988;6301-6305.
4. Lomasney J. W.et al. Proc. Natl. Acad. Sci. U. S. A. 87:1990;5094-5098.
5. Link R., Daunt D., Barsh G., Chruscinski A., Kobilka B. K. Mol. Pharmacol. 42:1992;16-27.
6. MacKinnon A. C., Spedding M., Brown C. M. Trends Pharmacol. Sci. 15:1994;119-123.
7. Svensson S. P., Bailey T. J., Porter A. C., Ricman J. G., Regan J. W. Biochem. Pharmacol. 51:1996;291-300.
8. Guyer C. A.et al. J. Biol. Chem. 265:1990;17307-17317.
9. Blaxall H. S., Cerutis D. R., Hass N. A., Iversen L. J., Bylund D. B. Mol. Pharmacol. 45:1994;176-181.
10. Blaxall H. S., Heck D. A., Bylund D. B. Life Sci. 53:1993;255-259.
11. Svensson S. P. S.et al. Br. J. Pharmacol. 110:1993;54-60.
12. Blaxall H. S., Murphy T. J., Baker J. C., Ray C., Bylund D. B. J. Pharmacol. Exp. Ther. 259:1991;323-329.
13. Marjamäki A., Luomala K., Ala-Uotila S., Scheinin M. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 266:1993;219-226.
14. Jansson C. C.et al. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 266:1994;165-174.
15. French N. Pharmacol. Ther. 68:1995;175-208.
16. Wikberg J. E. S., Uhlén S., Chajlani V. Eur. J. Pharmacol. 193:1991;335-340.
17. Funk L., Trendelenburg A-U., Limberger N., Starke K. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;58-66.
18. Alberts P. Gen. Pharmacol. 24:1993;1-8.
19. Nicholas A. P., Hökfelt T., Pieribone V. A. Trends Pharmacol. Sci. 17:1996;245-255.
20. Boyajian C. L., Loughlin S. E., Leslie F. M. J. Pharmacol. Exp. Ther. 241:1987;1079-1081.
21. Wamsley J. K., Alburges M. E., Hunt M. A., Bylund D. B. Pharmacol. Biochem. Behav. 41:1992;267-273.
22. Zilles K., Qu M., Schleicher A. J. Hirnforschung. 34:1993;123-132.
23. Link R. E.et al. Mol. Pharmacol. 48:1995;48-55.
24. McCune S. K., Voigt M. M., Hill J. M. Neurosci. 57:1993;143-151.
25. Nicholas A. P., Pieribone V., Hökfelt T. J. Comp. Neurol. 328:1993;575-594.
26. Scheinin M.et al. Mol. Brain Res. 21:1994;133-149.
27. Winzer-Serhan U. H., Raymon H. K., Broide R. S., Chen Y., Leslie F. M. Neuroscience. 76:1997;241-260.
28. Winzer-Serhan U. H., Raymon H. K., Broide R. S., Chen Y., Leslie F. M. Neuroscience. 76:1997;261-272.
29. Wang R.et al. Neuroscience. 74:1996;199-218.
30. Rosin D. L.et al. Neuroscience. 56:1993;139-155.
31. Rosin D. L.et al. J. Comp. Neurol. 372:1996;135-165.
32. Aoki C., Go C., Venkatesan C., Kurose H. Brain Res. 650:1994;181-204.
33. Guyenet P. G.et al. Brain Res. 638:1994;285-294.
34. Talley E. M., Rosin D. L., Lee A., Guyenet P. G., Lynch K. R. J. Comp. Neurol. 372:1996;111-134.
35. von Zastrow M., Kobilka B. K. J. Biol. Chem. 269:1994;18448-18452.
36. Wozniak M., Limbird L. E. J. Biol. Chem. 271:1996;5017-5024.
37. Link R. E.et al. Science. 273:1996;803-805.
38. MacMillan L. B., Hein L., Smith M. S., Piascik M. T., Limbird L. E. Science. 273:1996;801-803.
39. Suprenant A., Horstman D. A., Akbarali H., Limbird L. E. Science. 257:1992;977-980.
40. Lakhlani P. P., Lovinger D. M., Limbird L. E. Mol. Pharmacol. 50:1996;96-103.
41. Hunter J. C.et al. Br. J. Pharmacol. (Proc. Suppl.). 121:1997;P89.
42. Sallinen, J. et al. Mol. Pharmacol. 51 (in press).
43. Lanier S. M., Lafontan M., Limbird L. E., Paris H. J. Pharmacol. Exp. Ther. 277:1996;10-16.
44. Burke J.et al. Ann. New York Acad. Sci. 763:1995;78-95.
45. David R.et al. Arch. Ophthalmol. 111:1993;1387-1390.
46. Freedman R. R., Moten M., Migaly P., Mayes M. Arthritis Rheum. 36:1993;685-690.
47. Nutt D. J. J. Psychophamacol. 8:1994;193-195.
48. MacDonald E., Scheinin M. J. Physiol. Pharmacol. 46:1995;241-258.
49. Capecchi M. Science. 244:1989;1288-1292.
50. Capecchi M. Trends in Genetics. 5:1989;70-76.
51. Nagy A. E.et al. Development. 110:1990;815-821.
52. Nagy, A. and J. Rossant. (1993). in Gene Targeting. Practical Approach Series. Oxford, Oxford University Press.
53. Brandon E. P., Idzerda R. L., McKnight G. S. Current Biol. 5:1995;1-27.
54. Gerlai R. Trends Neurosci. 19:1996;177-181.
55. Link R. E.et al. Mol. Pharmacol. 48:1995;48-55.
56. Hein L., Barsh G. S., Pratt R. E., Dzau V. J., Kobilka B. K. Nature. 377:1995;744-747.
57. Rohrer D. K.et al. Proc. Natl. Acad. Sci. U.S.A. 93:1996;7375-7380.
58. Bond R. A.et al. Nature. 374:1995;272-276.
59. Milligan G., Bond R. A., Lee M. Trends Pharmacol. Sci. 16:1995;10-13.
60. Sallinen J.et al. Mol. Pharmacol. 51:1997;36-46.
61. Akhtar S., Agrawal S. Trends Pharmacol. Sci. 18:1997;12-18.
62. Pasternak G. W., Standifer K. M. Trends Pharmacol. Sci. 16:1995;344-350.
63. Weiss, B., S.P., Z. and L.W., Z. (1997) Life Sci., 60, 433-455.
64. Albert P. R., Morris S. J. Trends Pharmacol. Sci. 15:1994;250.